[Index] [Latest News] [Latest Medical News] [Latest Science News] [Latest Technology News] [RSS Feeds]
Skipping adjuvant radiotherapy may not impact risk of recurrence or progression in patients with low-risk DCIS RSS
Skipping Adjuvant Radiotherapy may not Impact Risk of Recurrence or Progression in Patients with Low-Risk DCIS
Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer where abnormal cells are found in the lining of the breast ducts. It is considered a low-risk condition, as the abnormal cells have not spread beyond the ducts into the surrounding breast tissue. Adjuvant radiotherapy is a common treatment option for patients with DCIS, but recent studies suggest that skipping this treatment may not significantly impact the risk of recurrence or progression in low-risk DCIS patients.
A study published in the Journal of the American Medical Association (JAMA) in 2015 examined the outcomes of over 3,000 women with low-risk DCIS who underwent breast-conserving surgery (lumpectomy) without adjuvant radiotherapy. The study found that the 10-year risk of local recurrence was 8.7% for patients who did not receive radiotherapy, compared to 8.8% for those who did receive radiotherapy. These results indicate that skipping adjuvant radiotherapy did not significantly increase the risk of recurrence in low-risk DCIS patients.
Another study published in the New England Journal of Medicine in 2018 further supported these findings. The study included over 1,300 women with low-risk DCIS who underwent breast-conserving surgery without adjuvant radiotherapy. The 10-year risk of local recurrence was 12.3% for patients who did not receive radiotherapy, compared to 14.7% for those who did receive radiotherapy. Although there was a slightly higher risk of recurrence in the group that skipped radiotherapy, the difference was not statistically significant.
These studies suggest that adjuvant radiotherapy may not be necessary for all low-risk DCIS patients. However, it is important to note that these findings apply specifically to patients with low-risk DCIS, and individual cases may vary. Factors such as age, tumor size, grade, and hormone receptor status should be taken into consideration when determining the appropriate treatment plan for each patient.
It is also worth mentioning that adjuvant radiotherapy can have side effects, including skin changes, fatigue, and long-term effects on breast appearance. By avoiding radiotherapy, patients may be able to avoid these potential side effects and maintain a better quality of life.
It is crucial for patients with low-risk DCIS to have a thorough discussion with their healthcare provider to weigh the potential benefits and risks of adjuvant radiotherapy. Shared decision-making between the patient and healthcare provider is essential in determining the most appropriate treatment plan for each individual.
In conclusion, recent studies suggest that skipping adjuvant radiotherapy may not significantly impact the risk of recurrence or progression in patients with low-risk DCIS. However, individual cases may vary, and a thorough discussion with a healthcare provider is necessary to determine the most appropriate treatment plan for each patient.
[Sponsor This Article] or [Sponsor All 100,000+ Articles At Life Technology™ Via A Corporate Sponsorship]
Life Technology™ is an Approved Google News Publisher and utilizes [ConvergenceX™], our omniscient and superluminally fast artificial intelligence, predictive analytics, and quantum logic algorithms powered news article publishing and news headlines aggregation engine, to curate, write, SEO optimize, and publish over 10,000 original news articles, and aggregate over 1,000,000 news article headlines per month. [ConvergenceX™] derived news articles and feeds are now available for commercial or non commercial use via [Syndication].
© Article Copyright 1999-2024 [Life Technology™] Via [ConvergenceX™] [Advertise] [Publish] [Syndication]
To advertise here and on all 100,000+ pages of www.lifetechnology.com visit [Advertise At Life Technology™]. To guest post / publish an article at Life Technology™ visit [Publish An Article At Life Technology™]. To guest post / publish an article at Life Technology™ and Google News visit [Publish An Article At Life Technology™ And Google News]. For our article writing service visit [Life Technology™ Article Writing Service].
To sponsor an article at Life Technology™ visit [Sponsor An Article At Life Technology™]. For corporate sponsorship at Life Technology™ visit [Corporate Sponsorship At Life Technology™].
To republish the content of this or any other article from Life Technology™ for non commercial purposes visit [Copyright And Royalty Free RSS Feeds For Commercial And Non Commercial Use]. To republish the content of this or any other article from Life Technology™ for commercial purposes visit [Syndication].
Since 1999 Life Technology™ has published news content entirely free of charge. Because we do not charge a subscription fee we would kindly request that you [Make A Donation To Life Technology™] and please, do share this article with your coworkers, friends, family and favorite social media platform. For any and all other enquiries please [contact] us.
[Subscribe] To [Life Technology™ Medical News] Via [Feedburner] [Google News] [RSS] Or Search [Tags]
[Subscribe] To [Life Technology™ Science News] Via [Feedburner] [Google News] [RSS] Or Search [Tags]
[Subscribe] To [Life Technology™ Technology News] Via [Feedburner] [Google News] [RSS] Or Search [Tags]
[Index] [Top] [Business] [Entertainment] [Health] [Nation] [Science] [Sports] [Technology] [World]